ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by jjwilsonon Jun 17, 2018 5:05pm

111 Views

Post# 28183627

RE:RE:RE:RE:Proxy Voting

Jordon3:

Yes, I remember you mentioning this to me before - that you sent an email and didn't get a reply. Discouraging after taking the time to send something. I guess there's some consolation in knowing that you expressed your feelings on the matter even if you didn't get a message back.

My feeling is that if a shareholder is unhappy enough to vote "no" to the option plan that they should at least take the time to send an email explaining why so that the rationale behind their vote is being communicated. If you want to push the management in a certain direction it's got to be clear what direction that is and why. That's all. Simply voting "no" is doing half the job.

Bullboard Posts

Morning Market Outlook for Nov. 14, 2024